BeiGene (BGNE, Financial) saw its stock increase by 1.45% to $209.82. The 66th American Society of Hematology (ASH) Annual Meeting will be held from December 7-10, 2024, in San Diego, USA. Recently, ASH released abstracts of some studies that will be presented at the conference, featuring several domestic pharmaceutical companies, including BeiGene.
At the upcoming ASH Annual Meeting, BeiGene will showcase clinical data from its innovative hematology product portfolio, targeting various B-cell malignancies. Key highlights include the 5-year results from the Phase 3 SEQUOIA study showing continued benefits for all CLL patients treated with BeiGene's Brukinsa. Additionally, two oral presentations will demonstrate the safety and efficacy of the BTK degradative compound (CDAC) BGB-16673. Another presentation will emphasize the deep and durable remission and controllable tolerance exhibited in a Phase 1 trial of the BCL2 inhibitor sonrotoclax combined with Brukinsa for untreated CLL/SLL patients.
